Insights

Insights

National Writing Day – Connecting Patients with New Therapies

National Writing Day – Connecting Patients with New Therapies

Happy National Writing Day 2021! In line with this year’s theme of ‘connections’, our medical writers have taken a look back at our UK health technology assessments (HTA) submissions over the past 12 months… Connections ... Read more

Improving your search strategy: Date limit filters (2/2)

Improving your search strategy: Date limit filters (2/2)

This blog post follows on from ‘Improving your search strategy: Randomised controlled trial filters’. Electronic database searches can be run on multiple platforms. This article focusses primarily on applying date limits in Ovid.   When to ... Read more

Improving your search strategy: Randomised controlled trial filters (1/2)

Improving your search strategy: Randomised controlled trial filters (1/2)

A search filter is a pre-written search strategy (string of search terms) that is designed to retrieve studies with a particular methodology or focus from a specific database and platform (1). The most common filters are designed to retrieve ... Read more

Applying Health Technology Assessment requirements to your Global Value Dossier

Applying Health Technology Assessment requirements to your Global Value Dossier

The global value dossier (GVD) is an essential tool used to internally align the global strategy and externally communicate the value of a product. The GVD presents evidence-based messaging to convey the product value story and is a primary ... Read more

Collaborative webinar: Economic modelling in rare diseases

Collaborative webinar: Economic modelling in rare diseases

It can be challenging to develop an economic model in rare diseases that optimises HTA and reimbursement outcomes. It can be difficult to fully capture the effects of the disease and the benefits of treatment whilst using sufficiently robust ... Read more

COVID-19, evidence-based medicine and standards for HTA

COVID-19, evidence-based medicine and standards for HTA

When Archibald Cochrane formulated his vision for evidence-based medicine (EBM), it was driven by an absence of reliable, robust evidence supporting frequently accepted medical interventions. His observations provoked meticulous evaluations of ... Read more

Evidence search for medical devices: Challenges and recommendations

Evidence search for medical devices: Challenges and recommendations

In principle, the process of searching for published evidence for medical devices is no different from other health technologies. The NICE process guidelines do not specify alternative sources or a different level of rigour for any kind of ... Read more

Exploring the NICE MTEP process for developing medical device guidance

Exploring the NICE MTEP process for developing medical device guidance

The NICE Medical Technologies Evaluation Programme (MTEP) evaluates novel medical devices and diagnostics for use within the National Health Service (NHS). There are currently 3 outputs from the programme: medical technologies guidance (MTGs), ... Read more

The NICE HST Process (3/3) – Challenges associated with appraising treatments for ultra-rare indications

The NICE HST Process (3/3) – Challenges associated with appraising treatments for ultra-rare indications

In previous blog posts, we explored the origins of NICE’s Highly Specialised Technologies (HST) process and compared it with the Single Technology Assessment (STA) process. In this blog, we review the first 10 HST appraisals and identify key ... Read more

Reporting current research with living systematic literature reviews

Reporting current research with living systematic literature reviews

Although considered the gold standard of quality research, systematic literature reviews (SLRs) are very resource intensive (e.g. long timeline, high budget) [1]. This, in combination with the broader issue that “research outpaces ... Read more

The NICE HST process (2/3) – Differences in assessment of cost-effectiveness between the HST and STA

The NICE HST process (2/3) – Differences in assessment of cost-effectiveness between the HST and STA

In a previous post, we discussed the origins of the NICE Highly Specialised Technologies (HST) process for the evaluation of therapies for rare diseases. In this blog, we examine the key differences between the Single Technology Appraisal (STA) ... Read more

The NICE HST process (1/3) – Origins and current state of affairs

The NICE HST process (1/3) – Origins and current state of affairs

Treatments for very rare conditions represent a unique challenge to payers. Extremely low patient numbers mean that often only Phase 1/2 trial data are available, and that natural history, quality of life and resource use data are limited. ... Read more

Is the NICE FTA process resulting in faster access to the most cost-effective therapies?

Is the NICE FTA process resulting in faster access to the most cost-effective therapies?

On the 1st April 2017, the National Institute for Health and Care Excellence (NICE) introduced a fast-track appraisal (FTA) process, with the aim of providing quicker access for patients to the most cost-effective new treatments. Two years on, ... Read more

Will discount rates change for UK HTA

Will discount rates change for UK HTA

The rate at which future costs and outcomes are discounted has long stood at 3.5% for UK HTA agencies (1,2). The source of this discount rate is the Social Time Preference Rate (STPR), presented in previous versions of the Treasury’s Green Book, Read more

Why multi-company collaboration for HTA evidence generation in rare diseases is a good thing

Why multi-company collaboration for HTA evidence generation in rare diseases is a good thing

Project HERCULES is a unique international multi-stakeholder collaborative project set up by Duchenne UK to develop tools and evidence to support Health Technology Assessment (HTA) and reimbursement decisions for new treatments for Duchenne ... Read more

Rapid Reviews: What you need to know

Rapid Reviews: What you need to know

As described in the Cochrane Collaboration Handbook, a systematic literature review (SLR) attempts to collate all empirical evidence that fits pre-specified eligibility criteria in order to answer a specific research question (primarily to aid ... Read more

Explaining ICER, America’s answer to NICE

Explaining ICER, America’s answer to NICE

The Boston-based Institute for Clinical and Economic Review, otherwise known as ICER, has caught the attention of important stakeholders in the past few years. Between reports for high-impact drugs that have stirred public opinion (such as a ... Read more

The importance of peer-review for your search strategy

The importance of peer-review for your search strategy

The search strategy is the foundation of a well-conducted systematic literature review (SLR) and is the fundamental element that can affect the overall quality of the results of the final review (1, 2). The aim of a search string is to achieve a Read more

Mixture cure models: Modelling survival when some patients are cured

Mixture cure models: Modelling survival when some patients are cured

The standard survival analysis techniques used in oncology modelling, such a parametric survival curves, provide a useful way of estimating transition probabilities to populate economic models. These models are predicated on the idea that at ... Read more

Duchenne UK’s Project HERCULES awarded prestigious rare disease award

Duchenne UK’s Project HERCULES awarded prestigious rare disease award

Project HERCULES is a unique international multi-stakeholder collaborative project set up by Duchenne UK to develop tools and evidence to support Health Technology Assessment (HTA) and reimbursement decisions for new treatments for Duchenne ... Read more

htasurv: a Stata module for performing survival analysis in economic evaluations

htasurv: a Stata module for performing survival analysis in economic evaluations

htasurv is an open source Stata module for assessing alternative parametric distributions when extrapolating survival data for use in health economic models. The function distfind loops through alternative distributions (specified by the user) ... Read more

Ten guiding principles for model write-ups & economic sections of HTA submissions

Ten guiding principles for model write-ups & economic sections of HTA submissions

The following pointers aim to provide practical guidance to strengthen the communication of your economic case, avoid the introduction of mistakes and make the deadline. 1. Validate your model first. Then get someone else to validate it. Read more

Model methods: Part 2 – finding an elegant solution

Model methods: Part 2 – finding an elegant solution

When developing a model methodology, there should be a Eureka moment. The moment when you find a model structure that reflects natural history, captures the relative benefits and harms of the new intervention versus standard of care (SoC) and ... Read more

Model methods: Part 1 – to include or not to include?

Model methods: Part 1 – to include or not to include?

It’s an accepted principle that the structure of a cost-effectiveness model should reflect the natural history of disease. Further, that it should capture the differences in outcome, cost and resource use expected to result from the use of a new Read more